Aggregating Local Innovation Ecosystems on a Platform to Drive Quality Development in Pan-Vascular Diagnosis and Treatment
ShanghaiJune 1, 2026 /PRNewswire/ — During the 20th Oriental Congress of Cardiology, Philips announced that its image-guided therapy systems have surpassed 6,000 installations in China. Moving forward, the company will collaborate with multiple partners to deepen synergies and support the development of pan-vascular interventional diagnosis and treatment capabilities across the entire chain of diagnosis, treatment, and follow-up, injecting new momentum into the high-quality advancement of interventional medicine in China.
Celebrating 6,000 Installations of Philips Image-Guided Therapy Systems in China
Liu Ling, Member of the Philips Global Executive Committee and President of Philips Greater China, stated: “Philips has been deeply rooted in the field of image-guided therapy for over 70 years, maintaining a leading position in the industry through continuous innovation. We are delighted to witness the significant milestone of 6,000 installations of Philips image-guided therapy systems in China. This is not only a strong recognition of our long-term commitment to the Chinese market but also marks a new starting point for development. Looking ahead, we will leverage the synergistic innovation of interventional systems, clinical consumables, and interventional AI as a driving force, accelerate the layout of local ecosystems, and use the platform to aggregate local innovation resources, thereby supporting the quality development of pan-vascular diagnosis and treatment. While steadfastly fulfilling our ‘In China, for China’ commitment, we will promote the deeper application and exchange of Chinese innovation experience on a global scale, connecting global resources with local innovation through an open ecosystem.”
Liu Ling, Member of the Philips Global Executive Committee and President of Philips Greater China, Delivers a Speech
Milestone of 6,000 Installations: A Long-Term Commitment to Deepening the Field of Image-Guided Therapy
As the burden of diseases such as cardiovascular conditions, neurological disorders, and tumors continues to rise, clinical demands for interdisciplinary collaboration and efficient, precise pan-vascular diagnosis and treatment have increased. Image-guided technology is rapidly evolving from a single surgical support tool into a core platform for multidisciplinary integration. Against this backdrop, Philips’ image-guided therapy systems have officially surpassed 6,000 installations in China, marking a significant testament to its deep engagement in the Chinese market. Currently, these devices are widely deployed across medical institutions at all levels nationwide, with an average of one in every two interventional procedure rooms equipped with Philips devices, serving as a crucial pillar for enhancing pan-vascular interventional diagnosis and treatment capabilities in China.
As a representative of the hospital receiving the 6,000th installation, Dr. Chen Qiongdou from Guangxi Beiliu People’s Hospital remarked: “Good equipment combined with strong capabilities can better serve patients in Guangxi. The application of Philips’ image-guided therapy systems has laid a solid technical foundation for us to perform complex procedures such as complex coronary interventions. Relying on the collaborative platform established by the national center, county-level hospitals are becoming key fulcrums in the regional pan-vascular treatment network. While upgrading hardware capabilities, we have also fostered the development of technical talent, enabling frontline doctors to collaborate efficiently with provincial-level experts, allowing local residents to access high-quality interventional diagnosis and treatment services close to home.”
Installation and Commissioning of China’s 6,000th Philips Image-Guided Therapy System
Behind the scale of 6,000 installations lies the systematic capability built through long-term technical accumulation. Through continuous technological innovation and clinical practice, Philips has developed comprehensive application capabilities covering multiple departments and scenarios. These systems not only meet the demands of complex interventional procedures but also maintain stable and reliable performance over long-term use, ensuring consistency in diagnosis and treatment quality. The systems integrate key technologies such as SmartCT, EchoNavigator, VesselNavigator, DoseWise, and 3D Roadmap. By continuously optimizing the user interface and workflow, the equipment has been upgraded from a single operational tool to a “central control platform” that supports intraoperative decision-making. This enhances technical performance while improving user experience, effectively reducing human operational risks and elevating overall safety levels. Addressing the industry challenge of balancing image clarity with radiation dose, relevant clinical algorithms ensure image quality while minimizing radiation exposure and contrast agent usage by up to 83%, reducing the burden on patients’ kidneys and the risk of complications. Additionally, based on real-world clinical feedback accumulated from over 6,000 devices, the products undergo continuous iterative optimization, gradually forming an innovation pathway driven by user needs.
Advancing Collaborative Innovation in Interventional Medicine Through Ecosystem Building and Strategic Partnership Upgrades
The accumulation of 6,000 installations reflects not only commercial scale and systematic capability but also Philips’ confidence as an “ecosystem co-builder for platform-based innovation.” Since its launch in 2017, the core Philips image-guided therapy platform, Azurion, has been deployed in over 80 countries and regions worldwide, serving an average of over 6.4 million patients annually. Every second, a patient undergoes interventional treatment supported by Philips’ image-guided solutions, with clinical safety and practicality extensively validated. Leveraging global technical expertise and clinical insights gained from large-scale application in China, Philips China is collaborating with local clinical, research, and industrial innovation forces to build an integrated solution ecosystem covering the entire process of diagnosis, treatment, and follow-up, driving interventional medicine from “technology-driven” to “value-oriented” transformation.
In November 2025, Philips China formally signed a strategic cooperation memorandum with the National Clinical Research Center for Medical Assistance Technology (Interventional Therapy), outlining four key collaboration areas: joint R&D and technical cooperation, demonstration centers for digital catheterization labs, capacity building for interventional therapy in county-level medical institutions, and international cooperation. Currently, China’s experience in county-level interventional diagnosis and treatment is gradually becoming ready for external promotion. Technology platforms represented by Philips serve as critical infrastructure, supporting the downward extension of high-quality diagnostic and treatment capabilities to grassroots levels and enabling a two-way expansion of Chinese experience—”sinking down and going global.”
In terms of local ecosystem building, Philips announced at the forum strategic partnerships with Genesis MedTech and RuiXin Medical Technology, focusing respectively on comprehensive solutions for structural heart disease and upgrades in coronary AI functional diagnostics. This creates strategic complementarity among interventional imaging platforms, high-end clinical consumables, and diagnostic AI, jointly advancing the innovation and upgrading of integrated interventional diagnosis and treatment solutions. Looking ahead, the partnerships will further explore innovative possibilities for “AI+” medical applications.